AlphAIalphai — Financial news for AI agents
rttnews.comJUN 102 min read$STTK

Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr

Shattuck Labs (STTK) priced its previously announced public offering of 10.88 million shares at $4.00 each, and said it will also issue pre-funded warrants for up to 7.87 million shares at $3.9999 per warrant. The company expects about $75 million in gross proceeds and said the deal should close June 11. Underwriters have a 30-day option for up to 2.81 million additional shares.

Original reporting
rttnews.com
Published Jun 10, 2026, 8:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 9:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$STTK
Bearish
high confidence
Mentioned
$STTK
Relevance
8/10
alphai data visualization · based on rttnews.com
Decision brief

The 30-second read

$STTKBearishMed
01

Why it matters

The fixed offering price ($4.00) versus the prior close ($4.27) implies immediate dilution pressure, while the ~$75M gross proceeds may reduce near-term financing uncertainty.

02

Market read

A priced equity raise with warrants is a direct, tradable catalyst for dilution/overhang and cash-runway expectations.

03

What to watch

Watch the overhang into closing and any follow-on guidance on use of proceeds; warrant structure can also affect hedging/flow dynamics.

Relevance 8/10Novelty 8/10Timing: expected to close June 11

Background

The company had previously announced the offering; this article reports the final pricing and warrant terms.

Company-level read

Ticker impact

$STTKBearishHigh confidence
Context

Shattuck Labs priced a public offering of 10.88M shares at $4.00 and pre-funded warrants, raising ~$75M gross and diluting shares.

Expected impact

Near-term downside/volatility risk around dilution and closing; upside depends on whether proceeds materially extend funding and reduce financing risk.

Evidence & confidence

The article discloses the offering size, price, warrant terms, and expected gross proceeds, which directly affect dilution and capital structure.

Market effects

Sector

Adds another clinical-stage biotech example of equity financing, reinforcing dilution risk as a recurring theme in the group.

Regional

Primarily impacts US Nasdaq biotech sentiment; limited spillover beyond small-cap biotech complex.

Global

Low—financing is company-specific and not tied to a global macro/regulatory shock.

Counterpoint

What could challenge this read

If the proceeds meaningfully extend cash runway or de-risk upcoming clinical milestones, the market may re-rate the stock despite dilution.

Key entities

  • company
    Shattuck Labs

    Clinical-stage biotech that priced a common stock public offering and pre-funded warrants.

  • transaction
    Public offering

    10.88M shares at $4.00 plus pre-funded warrants for up to 7.87M shares; underwriters have a 30-day option for 2.81M more shares.

Read at source← All news

Related articles

AUG 12
$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

investing.com4 min
AUG 11
$STTKMed

Shattuck Labs, Inc. (STTK): Results of Operations and Financial Condition

Shattuck Labs, Inc. (STTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sttk_2q2026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism i

SEC EDGAR 8-K6 min
AUG 11
$STTKMed

Why is Shattuck Labs stock slipping today?

Shattuck Labs (STTK) shares fell 1.8% pre-open after its Q2 2026 earnings. The company reported a net loss of $15.2 million versus $12.5 million a year earlier, and R&D rose 34% to $11.7 million. It cited favorable Phase 1 safety for SL-325 and said Phase 2b in Crohn’s is on track. Cash and investments were about $208.3 million.

investing.com5 min
AUG 11
$STTKMedAI 8/10

Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Shattuck Labs (NASDAQ: STTK) reported Q2 2026 results and clinical updates for SL-325 and SL-846. SL-325 Phase 1 showed a favorable safety profile, 3.7% antidrug antibodies, and durable TL1A/DR3 blockade; RECEPTIVE-CD1 Phase 2b in Crohn’s is expected to start Q3 2026. Cash and investments were $208.3M, funding operations into 2029.

finanznachrichten.de7 min
JUL 25
$STTKMed

Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

Shattuck Labs shares rose about 4.8% on Friday, closing near $7.43. The move followed an inaugural note from JPMorgan’s Brian Cheng, who rated STTK overweight and set a $10 price target. The note cited Shattuck’s lead IBD drug candidate SL-325, referencing recent healthy volunteer data on safety and target engagement.

fool.com3 min
JUN 10
$STTKMedAI 9/10

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs (NASDAQ: STTK) priced a public offering of 10,879,376 shares at $4.00 each and pre-funded warrants for up to 7,870,624 shares at $3.9999 each, with a $0.0001 exercise price. Gross proceeds are expected at about $75 million before underwriting costs. The deal is set to close June 11, 2026, with a 30-day option for 2,812,500 additional shares.

manilatimes.net4 min